Medicinal Chemistry Support Program for Therapeutic Development
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institute on Neurological Disorders and Stroke (NINDS) and the NIH Blueprint Neurotherapeutics Network (BPN) intend to issue a sole source modification to CURIA GLOBAL, INC. for the "Medicinal Chemistry Support Program for Therapeutic Development" (Contract No. HHSN271201800001I). This modification will increase the maximum value of the existing Single Award Indefinite Delivery, Indefinite Quantity (IDIQ) contract by $30,145,159, raising the total from $39,500,000 to $69,645,159. The purpose is to ensure the continuation of essential medicinal chemistry support services for scientific research and therapeutic development, preventing delays for ongoing and upcoming pre-clinical and clinical trials.
Scope of Work
The contract provides comprehensive medicinal chemistry services, including project management, compound logistics, synthesis, computational chemistry (CADD), and in vitro ADMET studies. These services are critical for advancing preclinical candidate compounds towards Investigational New Drug (IND) filings. The work is divided into two performance areas:
- Performance Area 1: Tech Transfer, Storage Handling and Distribution, Access Training, and IT Security for existing compound repositories, focusing on overall administration and project management.
- Performance Area 2: Medicinal Chemistry Support, encompassing planning, design, milligram and multi-gram scale synthesis of chemical analogs, in vitro ADME/toxicology testing for lead optimization, compound registration, and data entry.
Contract Details
- Type: Sole Source Modification to an existing Single Award IDIQ.
- Current Contractor: CURIA GLOBAL, INC.
- Original Ordering Period: March 16, 2018, to March 15, 2028 (unchanged).
- NAICS Code: 541715 (Research and Development in the Physical, Engineering, and Life Sciences), with a 1,000-employee size standard.
- Statutory Authority: 41 U.S.C. 3304(a)(1) and FAR 6.103-1 (Only one responsible source).
Response Information
This is not a request for competitive proposals. However, interested parties may submit capability statements or objections to the proposed sole source modification. Responses will be considered to determine if a competitive procurement is feasible.
- Response Due: June 4, 2026, by 1:00 p.m. Eastern Daylight Time.
- Submission: Electronically to Shaun Rostad at shaun.rostad@nih.gov.
- Requirements: Active SAM registration, Unique Entity Identifier (UEI), Taxpayer Identification Number (TIN), and certification of business size must be included.